Update on Biosafety and Emerging Infections for the Clinical Microbiology Laboratory.

Communicable Diseases, Emerging / diagnosis Containment of Biohazards Humans Laboratories / organization & administration Microbiology / organization & administration
Association of Public Health Laboratories Biosafety in clinical laboratories Biosafety program Ebola Emerging pathogen

Journal

Clinics in laboratory medicine
ISSN: 1557-9832
Titre abrégé: Clin Lab Med
Pays: United States
ID NLM: 8100174

Informations de publication

Date de publication:
12 2020
Historique:
entrez: 30 10 2020
pubmed: 31 10 2020
medline: 8 9 2021
Statut: ppublish

Résumé

Biosafety risks are prevalent in all areas of the clinical laboratories. Clinical laboratorians have become accustomed to accepting these risks. When an emerging pathogen appears, the concerns become elevated. Since the appearance of Ebola virus in the United States in 2014, biosafety practices have made progress. A recent Association of Public Health Laboratories survey shows that clinical laboratories are unprepared for current and emerging biosafety challenges. This article focuses on the biosafety program that clinical laboratory leaders should build to meet the needs of clinical laboratories; biosafety challenges of automated laboratory systems, facilities, personnel, and practices; and the relationship with occupational health.

Identifiants

DOI: 10.1016/j.cll.2020.08.005 PMID: 33121616
pubmed: 33121616
pii: S0272-2712(20)30059-7
doi: 10.1016/j.cll.2020.08.005
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

473-482

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure M.A. Pentella is a consultant for Charles River Analytics.

Auteurs

Michael A Pentella (MA)

College of Public Health, University of Iowa, Iowa City, IA, USA; State Hygienic Laboratory, University of Iowa, Coralville, IA, USA. Electronic address: michael-pentella@uiowa.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies transmissibles émergentes › Update on Biosafety and Emerging Infections...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Accidents › Prévention des accidents › Sécurité › Confinement de risques biologiques › Update on Biosafety and Emerging Infections...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Update on Biosafety and Emerging Infections...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Laboratoires › Update on Biosafety and Emerging Infections...
questionsmedicales.fr › Disciplines des sciences naturelles › Disciplines des sciences biologiques › Biologie › Microbiologie › Update on Biosafety and Emerging Infections...